

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁷ : C12Q 1/68, C07H 21/04		A1	(11) International Publication Number: WO 00/31297 (43) International Publication Date: 2 June 2000 (02.06.00)
(21) International Application Number: PCT/US99/26019 (22) International Filing Date: 23 November 1999 (23.11.99)		(74) Agents: GOLDHUSH, Douglas, H. et al.; Nikaido, Marmelstein, Murray & Oram LLP, Metropolitan Square, 655 Fifteenth Street, N.W., Suite 330 - G Street Lobby, Washington, DC 20005-5701 (US).	
(30) Priority Data: 60/109,432 23 November 1998 (23.11.98) US		(81) Designated States: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).	
(71) Applicants (for all designated States except US): UNIVERSITY OF MARYLAND, COLLEGE PARK [US/US]; Office of Technology Liaison, 4312 Knox Road, College Park, MD 20742 (US). UNIVERSITY OF MARYLAND, BALTIMORE [US/US]; Office of Research & Development, 515 West Lombard Street, Baltimore, MD 21201 (US). UNIVERSITY OF PITTSBURGH [US/US]; Office of Technology Management, Rm 9110, William Pitt Union, Pittsburgh, PA 15260 (US).		Published <i>With international search report.</i>	
(72) Inventors; and (75) Inventors/Applicants (for US only): SHULDINER, Alan [US/US]; 10600 Harpoon Hill, Columbia, MD 21044 (US). FERRELL, Robert, E. [US/US]; 206 Maple Avenue, Pittsburgh, PA 15218 (US). HAGBERG, James, M. [US/US]; 10941 Hilltop Lane, Columbia, MD 21044 (US). BROWN, Michael, D. [US/US]; 9751 Mountain Laurel Way, 3A, Laurel, MD 20723 (US).			
(54) Title: GENETIC MARKERS WHICH IDENTIFY INDIVIDUALS WHO IMPROVE THEIR DIABETES STATUS WITH EXERCISE			
(57) Abstract			
<p>A method of improving diabetes status in subjects with diabetes or at risk of developing diabetes, comprising identifying subjects having an allele and/or a genotype at a gene locus which positively correlates with greater success in improving diabetes status in diabetic individuals, as compared with other alleles and/or genotypes at the same gene locus, and engaging the subject in exercise training for a period of time sufficient to improve the subject's diabetes status. Genotypic distinctions may be found, for example, in the beta-2 and beta-3 adrenergic system receptor (ASR) gene, the peroxisome proliferator activator receptor gamma (PPAR-gamma) gene, the insulin receptor substrate-1 (IRS-1) gene and the fatty acid binding protein-2 (FABP-2) gene.</p>			

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakhstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		

**GENETIC MARKERS WHICH IDENTIFY INDIVIDUALS WHO
IMPROVE THEIR DIABETES STATUS WITH EXERCISE**

FIELD OF THE INVENTION

The present invention relates to identifying one or more genetic markers which correlate with greater success in improving diabetes status in individuals with and without diabetes.

5

BACKGROUND OF THE INVENTION

Studies have shown that individuals suffering from or at risk of developing diabetes can alleviate symptoms or otherwise improve their conditions through exercise. Unfortunately, some individuals, no matter how rigorously they exercise, are unable to improve their conditions, while others 10 benefit to a much greater extent than predicted. These results underscore the fact that many factors contribute to an individual's well-being. Such factors include, for example, behaviors such as diet and exercise, genetic makeup, and environment. While behavior and environment can be controlled, altered or regulated, an individual's genetic makeup is essentially predetermined and set 15 at birth. The present inventors hypothesized that upon identifying the genetic makeup of a population suffering from or at risk of developing diabetes and observing that some individuals of the population improve their diabetic status from a change of behavior to a much greater or lesser extent than expected, a correlation could be made between the presence or absence of certain genetic 20 markers and success in improving diabetic status.

An object of the present invention is to identify one or more genetic markers which positively correlate with greater success in improving diabetes status in individuals with and without diabetes.

25

SUMMARY OF THE INVENTION

The present inventors have discovered a number of genetic markers which positively correlate with greater success in improving diabetes status in

- 2 -

diabetic or at risk individuals, as compared with other genetic makeup at the same gene loci. Therefore, the present invention is directed to a method of improving diabetes status in a subject with diabetes or at risk of developing diabetes, the method comprising:

5 identifying a subject with diabetes or at risk of developing diabetes having an allele and/or a genotype at a gene locus which positively correlates with greater success in improving diabetes status in diabetic individuals, as compared with other alleles and/or genotypes at the same gene locus; and

10 engaging the subject in exercise training for a period of time sufficient to improve the diabetes status in the subject.

DETAILED DESCRIPTION OF THE INVENTION

The inventors have found that a number of genetic markers positively correlate with greater success in improving diabetes status in individuals with diabetes or at risk of developing diabetes, as compared with other genetic makeup at the same gene loci. Markers which the inventors have investigated include the beta-2 and beta-3 adrenergic system receptor (ASR) gene, the peroxisome proliferator activator receptor gamma (PPAR-gamma) gene, the insulin receptor substrate-1 (IRS-1) gene and the fatty acid binding protein-2 (FABP-2) gene.

The term "subject in need of improvement" means both subjects with diabetes and subjects at risk of developing diabetes. In a preferred embodiment, the subject is with diabetes.

The term "improved diabetes status" means an improvement in at least one characteristic area which is associated with diabetes. An improvement may be in one or more of the following characteristic areas (this list is non-exhaustive and includes overlapping and representative examples only): change in glucose metabolism, change in insulin metabolism, change in glucose levels from a baseline determination, change in insulin levels from a baseline determination, change in fasting plasma glucose levels, change in fasting

- 3 -

plasma insulin levels or change in acute insulin response to glucose. These improvements may be measured by, for example, glucose tolerance tests conducted before and after exercise training. An improvement in diabetes status in accordance with the invention may be found both in individuals with diabetes and in individuals at risk of developing diabetes.

The term "single course of exercise", as used throughout this application, means a cardiovascular exercise session of any type which is conducted during one day. An exercise session may comprise an aerobics class, treadmill training, step machine, or any other suitable cardiovascular exercise regimen.

10 For most cases, exercise may be completed in, for example, 30 minutes to 3 hours, with optional brief rest periods of 3-15 minutes, however this amount would vary depending on the health and endurance of the subject.

The term "moderate exercise" means about 5-9 single courses of exercise, preferably about 6-8, or 7 single courses of exercise, over the exercise period. The exercise period in the case of a moderate exercise protocol may be from about 5-45 days, preferably from about 5-30 days, 5-20 days, or 5-15 days.

20 The term "extensive exercise" means about 10 single courses of exercise or more, preferably at least 15, at least 20, or at least 25 single courses of exercise, over a defined period of time ("the exercise period"). The exercise period in the case of an extensive exercise protocol may be from about 50-400 days, preferably from about 70-350 days or 100-300 days.

25 The time between exercise courses depends on whether the exercise period is an extensive or moderate exercise period. In the case of extensive exercise periods, the time between exercise courses may be from about 1-3 days or more. In the case of moderate exercise periods, the time between exercise courses may be from 24 hours or more.

30 The present inventors have discovered that diabetic individuals or those at risk of developing diabetes with different genotypes for genes which control the manufacture of certain proteins exhibit different degrees of success in

- 4 -

improving their diabetes status through exercise. The inventors have surprisingly discovered that each genotype potentially can benefit from exercise, however, the amount of exercise which produces the most benefits varies according to genotype. These results could not have been predicted from 5 initial patient screening.

Beta adrenergic receptors have numerous functions in the body, and are activated by binding beta agonists, such as the catecholamines isoproterenol, norepinephrine and epinephrine. In mammals, the liberation of glucose and fatty acids can be triggered by the binding of epinephrine or norepinephrine to 10 beta adrenergic receptors on hepatic and adipose cells.

The inventors have found that subjects having a "12" genotype for a beta-2 adrenergic receptor gene exhibit a greater improvement in diabetes status than those with a "11" genotype, after extensive exercise. However, subjects having the "11" genotype for the beta-2 adrenergic receptor gene exhibit a 15 greater improvement in diabetes status than those with the "12" genotype, after moderate exercise.

Therefore, one method of improving diabetes status in a subject in need of such improvement according to the invention comprises identifying a subject having a "12" genotype for a beta-2 adrenergic receptor gene, wherein the 20 subject is in need of improved diabetes status and engaging the subject in extensive exercise training for a period of time sufficient to improve the diabetes status in the subject.

Another method of improving diabetes status in a subject in need of such improvement according to the invention comprises identifying a subject having a "11" genotype for a beta-2 adrenergic receptor gene, wherein the subject is in need of improved diabetes status and engaging the subject in moderate exercise training for a period of time sufficient to improve the diabetes status in the 25 subject.

The present inventors have also discovered that diabetic individuals with 30 different beta-3 adrenergic receptor genotypes exhibit different degrees of

- 5 -

success in improving their diabetes status through exercise. The inventors have found that those individuals having a "11" genotype exhibit greater improvement in diabetes status than those with "12" genotypes, after extensive exercise.

5 Therefore, an additional method of improving diabetes status in a subject in need of such improvement according to the invention comprises identifying a subject having a "11" genotype for a beta-3 adrenergic receptor gene, wherein the subject is in need of improved diabetes status and engaging the subject in extensive exercise training for a period of time sufficient to improve the
10 diabetes status in the subject.

15 Peroxisome proliferator activator receptors are members of the nuclear hormone receptor family of transcription factors, a diverse group of proteins that mediate ligand-dependent transcriptional activation and repression. They modulate DNA transcription by binding to specific peroxisome proliferator response elements on target genes. The best characterized of these receptors, PPAR-gamma, is known to play a critical role in adipocyte differentiation and fat deposition and is highly expressed in this tissue.

20 The inventors have found that diabetics or those at risk of developing diabetes having a "11" genotype at the PPAR-gamma locus improve their diabetes status more with extensive exercise training than those having a "12" genotype.

25 Therefore, a method of improving diabetes status in a subject in need of such improvement comprises identifying a subject having a "11" genotype for a PPAR-gamma gene, wherein the subject is in need of improved diabetes status and engaging the subject in extensive exercise training for a period of time sufficient to improve the diabetes status in the subject.

30 IRS-1 is a 185 kDa protein which is activated rapidly upon insulin stimulation of cells, and is a key mediator of an insulin-regulated biological activity. The amino-terminal region of the protein contains interaction modules that facilitate its binding to receptors of insulin, IGF-1 and others. The

- 6 -

remainder of the molecule contains numerous tyrosine containing motifs, which, when phosphorylated by the insulin receptor tyrosine kinase, serve as binding regions for a variety of cellular proteins containing a so-called "SH2" domain.

5 The inventors have found that subjects having a "12" genotype for the IRS-1 gene exhibit a greater improvement in diabetes status than those with a "11" genotype, after extensive exercise.

10 Therefore, in accordance with this aspect of the present invention, a method of improving diabetes status in a subject in need of such improvement comprises identifying a subject having a "12" genotype for an IRS-1 gene, wherein the subject is in need of improved diabetes status and engaging the subject in extensive exercise training for a period of time sufficient to improve the diabetes status in the subject.

15 Fatty acid binding protein (FABP) can be found in numerous places in the body. In the liver, this protein binds free fatty acids and their Coenzyme A derivatives, bilirubin, and some other small molecules in the cytoplasm. Intestinal FABP is an abundant cytosolic protein in small intestine epithelial cells. It may participate in the uptake, intracellular metabolism and/or transport of long-chain fatty acids.

20 The inventors have found that subjects having a "12" genotype for a FABP-2 gene exhibit a greater improvement in diabetes status than those with a "11" genotype, after extensive exercise.

25 Therefore, a method of improving diabetes status in a subject in need of such improvement, according to this aspect of the invention, comprises identifying a subject having a "12" genotype for a FABP-2 gene, wherein the subject is in need of improved diabetes status and engaging the subject in extensive exercise training for a period of time sufficient to improve the diabetes status in the subject.

- 7 -

EXAMPLES

Example 1. Variations in Improvement of Diabetes Status in Subjects with Different Beta-2 and Beta-3 ASR and PPAR-Gamma Genotypes After Extensive Exercise

5 DNA was obtained from obese sedentary men 50-65 yrs of age, and processed as follows.

Detection of Pro12Ala Substitution in PPAR-Gamma

10 Genotyping for the Pro12Ala substitution in PPAR γ 2 was performed by polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) analysis as previously reported (1). Briefly, genomic DNA (approximately 20 ng) was subjected to PCR using upstream primer 5'-GCCAATTCAAGCCCAGTC-3' and mutagenic downstream primer 5' - GATATGTTGCAGACAGTGTATCAGTGAAGGAATCGCTTCCG-5' using standard reagents and cycling conditions to yield a 270 bp product. If the C-G substitution at nucleotide 34 of the PPAR γ 2 gene is present, the mutagenic downstream primer introduces a BstU-1 restriction site (CG/GC). Digestion with BstU-1 was performed; the products were electrophoresed on a 2.5% agarose gel, the gel was stained with ethidium bromide, and DNA was visualized by UV transillumination. Expected digestion product sizes were 270 bp for Pro12 homozygotes, 227 and 43 bp for Ala12 homozygotes, and 270 bp, 227 bp, and 43 bp for heterozygotes.

Detection of Trp64Arg Substitution in Beta-3-ASR

25 Polymerase chain reaction was performed from approximately 20 ng of genomic DNA with upstream primer 5' -CGCCCAATACGCCAACAC-3' and downstream primer 5' -CCACCAGGAGTCCCATCACC-3' in the presence of 10% dimethylsulfoxide (2). The resulting 210 bp product was digested with BST NI. The digested products were subjected to electrophoresis through a 4% agarose gel. The gel was stained with ethidium bromide and DNA was

- 8 -

visualized by UV transillumination. The expected sizes were 99 bp, 62 bp, 30 bp, 12 bp and 7 bp for Trp64 homozygotes, 161 bp, 30 bp, 12 bp and 7 bp for Arg64 homozygotes, and 161 bp, 99 bp, 62 bp, 30 bp, 12 bp and 7 bp for heterozygotes.

5

Detection of Gln27Glu Substitution in Beta-2 ASR

Genotyping for the Gln27Glu substitution in the beta-2-adrenergic receptor was performed as described previously (3). Genomic DNA was amplified with upstream primer 5'-GGCCCATGACCAGATCAGCA-3' and downstream primer 5'-GAATGAGGCTTCCAGGCGTC-3' using standard conditions. The resulting 353 bp product was digested with Ita I and the reaction products subjected to agarose gel electrophoresis. The gel was stained with ethidium bromide and DNA was visualized by UV transillumination. The expected sizes were 174 bp, 97 bp, 55 bp and 27 bp for Gln27 homozygotes, 229 bp, 97 bp and 27 bp for Glu27 homozygotes, and 229 bp, 174 bp, 97 bp, 55 bp and 27 bp for heterozygotes.

10
15

Results

The subjects underwent 9 months of endurance exercise training to quantify, among other things, their improvements in plasma glucose and insulin responses to an oral glucose challenge. Subjects were initially stabilized on an American Heart Association low-fat diet and then underwent an oral glucose tolerance test with blood samples drawn for up to 3 hours after the ingestion of a standard glucose load. This diet was maintained throughout the 9 months of exercise training and subjects repeated the glucose tolerance test after training. The data in Table 1 represent the change in the integrated glucose and insulin areas above baseline that occurred with exercise training. Subjects with the beta-2 ASR "12" genotype decreased their glucose and insulin areas with exercise training substantially more than subjects with the beta-2 ASR "11" genotype. Furthermore, subjects with the beta-3 ASR "11" genotype decreased

20
25
30

- 9 -

their glucose areas less, but decreased their insulin areas substantially more with exercise training than subjects with the beta-3 ASR "12" genotype. Lastly, subjects with the PPAR-gamma "11" genotype decreased their glucose areas less, but decreased their insulin areas dramatically more with exercise training than subjects with the PPAR-gamma "12" genotype. Thus, these results indicate that beta-2 and beta-3 ASR and PPAR-gamma genotypes identify those individuals most likely to improve their diabetic status, in terms of glucose and insulin metabolism, with exercise training.

10 Table 1: Change with Exercise Training in Integrated Glucose and Insulin Areas in Response to an Oral Glucose Tolerance Test as a Function of Genotype

		Change with Exercise Training	
		Glucose Area	Insulin Area
$\beta 2$ Receptor Genotype			
15	11 genotype (n=6)	-285 \pm 791	-3224 \pm 1584
	12 genotype (n=8)	-1489 \pm 603	-6831 \pm 5349
$\beta 3$ Receptor Genotype			
	11 genotype (n=13)	-1012 \pm 559	-6863 \pm 3930
	12 genotype (n=2)	-2115 \pm 495	-1273 \pm 1192
PPAR γ Genotype			
20	11 genotype (n=13)	-1255 \pm 536	-9150 \pm 4308
	12 genotype (n=2)	-2692 \pm 472	172 \pm 891

25 Values are mean \pm SE. Values are expressed as the change with 9 months of exercise training in integrated glucose or insulin area above baseline for 3 hours following a standard oral glucose challenge. Thus, negative values indicate a response that is reduced after exercise training and positive values a response that is greater after training.

- 10 -

Example 2. Variations in Improvement of Diabetes Status in Subjects with Different IRS-1 and FABP-2 Genotypes After Extensive Exercise

The same subjects as in Example 1 were genotyped for IRS-1 and FABP-2 genes as follows.

5

Detection of Gly972Arg Substitution in IRS-1

A 220 bp region encompassing the Gly972Arg substitution was amplified from approximately 20 ng of genomic DNA with upstream primer 5'-GCAGCCTGGCAGGAGAGCCAT-3' and downstream primer 5'-CTCACCTCCTCTGCAGCAATG-3'. PCR products were digested with Bst NI. The digested products were run on a 4% agarose gel, stained with ethidium bromide, and visualized by UV transillumination. The expected digestion product sizes were 220 bp for Gly972 homozygotes, 164 bp and 56 bp for Arg972 homozygotes and 220 bp, 164 bp and 56 bp for heterozygotes.

10

Detection of Ala54Thr Substitution in FABP-2

A 180 bp region encompassing the Ala54Thr substitution was amplified by PCR from genomic DNA with upstream primer 5'-ACAGGTGTTAATATAGTGAAAAG-3' and downstream primer 5'-TACCTGAGTTCAGTTCCGTC-3' using standard conditions (4). The PCR product was digested with Hha I. The digestion products were electophoresed through a 4% agarose gel, the gel was stained with ethidium bromide, and DNA was visualized by UV transillumination. Expected DNA fragment sizes were 99 bp and 81 bp for Ala54 homozygotes, 180 bp for Thr54 homozygotes and 180 bp, 99 bp and 81 bp for heterozygotes.

15

20

Results

The exercise regimen for these subjects was described in Example 1. The data in the following Table 2 represent the change in the integrated glucose and insulin areas above baseline and fasting plasma insulin levels that occurred

25

- 11 -

with the exercise training. Subjects with the FABP-2 "12" genotype decreased their glucose and insulin areas and fasting insulin levels with exercise training substantially more than subjects with the FABP-2 "11" genotype. Furthermore, subjects with the IRS-1 "12" genotype decreased their glucose areas somewhat less, but decreased their insulin areas and fasting insulin levels substantially more with exercise training than subjects with the IRS-1 "11" genotype. Thus, these results indicate that IRS- 1 and FABP-2 genotypes identify those individuals most likely to improve their diabetic status, in terms of glucose and insulin metabolism, with exercise training.

10

Table 2: Change with Exercise Training in Integrated Glucose and Insulin Areas in Response to an Oral Glucose Tolerance Test and Fasting Plasma Insulin Levels as a Function of Genotype

15

20

FABP-2 Genotype	Change with Exercise Training		
	Glucose Area	Insulin Area	Fasting Insulin
11 genotype (n=6)	-221 ± 674	-2320 ± 1021	-1.6 ± 2.2
12 genotype (n=5)	-2232 ± 509	-10080 ± 8559	-7.5 ± 3.7
IRS-1 Genotype			
11 genotype (n=9)	-1437 ± 490	-2308 ± 854	-2.6 ± 2.0
12 genotype (n=2)	-49 ± 1588	-21771 ± 22230	-11.7 ± 7.1

Values are mean ± SE. Values are expressed as the change with 9 months of exercise training in integrated glucose or insulin area above baseline for 3 hours following a standard oral glucose challenge or the fasting plasma insulin level. Negative values indicate a response or level that is reduced after exercise training and positive values a response that is greater after training.

30

- 12 -

Example 3. Variations in Improvement of Diabetes Status in Subjects with Different Beta-2 ASR Genotypes After Moderate Exercise

In the study obese sedentary hypertensive African-American middle-aged women underwent 7 days of endurance exercise training to quantify, 5 among other things, their improvements in plasma glucose and insulin responses to an intravenous glucose challenge. DNA processing was in accordance with Example 1. Subjects were initially weight-stabilized on their own diet and then underwent an intravenous glucose tolerance test with blood samples drawn for up to 3 hours after the injection of a standard glucose load. 10 The women then repeated the glucose tolerance test after 7 days of exercise training. With training, women with the beta-2 ASR "11" genotype decreased their acute insulin response, during the first 10 minutes following the injection of the glucose load, and their fasting plasma insulin levels more than women with the beta-2 ASR "12" genotype. The results are presented in the following 15 Table 3. These results are further evidence that the beta-2 ASR genotype identifies those individuals most likely to improve their diabetic status, in terms of glucose and insulin metabolism, with exercise training.

20 Table 3: Change with Moderate Exercise Training in Acute Insulin Response and Fasting Insulin Levels as a Function of Genotype

	Change with Exercise Training		
	β2 Receptor Genotype	Acute Insulin Response	Fasting Insulin
11 genotype (n=5)		-36 ± 64	0.2 ± 1.5
12 genotype (n=3)		-169 ± 201 (P=0.20)	-5.7 ± 3.1 (P=0.009)

25 Values are mean ± SD. Values are expressed as the change with 7 days of exercise training in acute insulin response for the 10 minutes following the injection of glucose and fasting plasma insulin levels. Negative values indicate a response or level that is reduced after 7 days of exercise training and positive 30

- 13 -

values a response or level that is greater after training.

The following references cited in the specification are hereby incorporated by reference:

5 (1) Yen et al. (1997) *Biochem. Biophys. Res. Commun.* **241**, 270-274.
(2) Widen et al. (1995) *N. Engl. J. Med.* **333**, 348-351.
(3) Large et al. (1997) *J. Clin. Invest.* **100**, 3005-3013.
(4) Baier et al. (1995) *J. Clin. Invest.* **95**, 1281-1287.

We claim:

1. A method of improving diabetes status in a subject in need of such improvement, the method comprising:

5 identifying a subject with diabetes or at risk of developing diabetes having an allele and/or a genotype at a gene locus which positively correlates with greater success in improving diabetes status in diabetic individuals, as compared with other alleles and/or genotypes at the same gene locus; and

10 engaging the subject in exercise training for a period of time sufficient to improve the diabetes status in the subject.

10

2. A method of improving diabetes status in a subject in need of such improvement, the method comprising:

15 identifying a subject with diabetes or at risk of developing diabetes having a "12" genotype for a beta-2 adrenergic receptor gene, wherein the subject is in need of improved diabetes status; and

20 engaging the subject in extensive exercise training for a period of time sufficient to improve the diabetes status in the subject.

20

3. A method of improving diabetes status in a subject in need of such improvement, the method comprising:

25 identifying a subject with diabetes or at risk of developing diabetes having a "11" genotype for a beta-3 adrenergic receptor gene, wherein the subject is in need of improved diabetes status; and

25

engaging the subject in extensive exercise training for a period of time sufficient to improve the diabetes status in the subject.

30

4. A method of improving diabetes status in a subject in need of such improvement, the method comprising:

30

identifying a subject with diabetes or at risk of developing diabetes having a "11" genotype for a peroxisome proliferator activator receptor gamma

- 15 -

gene, wherein the subject is in need of improved diabetes status; and
engaging the subject in extensive exercise training for a period of time
sufficient to improve the diabetes status in the subject.

5 5. A method of improving diabetes status in a subject in need of such
improvement, the method comprising:

identifying a subject with diabetes or at risk of developing diabetes
having a "12" genotype for a fatty acid binding protein-2 gene, wherein the
subject is in need of improved diabetes status; and

10 engaging the subject in extensive exercise training for a period of time
sufficient to improve the diabetes status in the subject.

6. A method of improving diabetes status in a subject in need of such
improvement, the method comprising:

15 identifying a subject with diabetes or at risk of developing diabetes
having a "12" genotype for a insulin receptor substrate-1 gene, wherein the
subject is in need of improved diabetes status; and

engaging the subject in extensive exercise training for a period of time
sufficient to improve the diabetes status in the subject.

20

7. A method of improving diabetes status in a subject in need of such
improvement, the method comprising:

identifying a subject with diabetes or at risk of developing diabetes
having a "11" genotype for a beta-2 adrenergic receptor gene, wherein the
25 subject is in need of improved diabetes status; and

engaging the subject in moderate exercise training for a period of time
sufficient to improve the diabetes status in the subject.

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US99/26019

A. CLASSIFICATION OF SUBJECT MATTER

IPC(7) : C12Q 1/68; C07H 21/04
US CL : 435/6; 536/23.5

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 435/6; 536/23.5

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)
Please See Continuation Sheet

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	SAKANE et al. Effects of Trp ⁴⁴ Arg Mutation in the beta3-Adrenergic Receptor Gene on Weight Loss, Body Fat Distribution, Glycemic Control, and Insulin Resistance in Obese Type 2 Diabetic Patients. Diabetes Care. December 1997, Vol. 20, No. 12, pages 1887-1890, see entire document.	1, 3
A	HANSEN, B.C. Obesity, Diabetes, and Insulin Resistance: Implications from Molecular Biology, Epidemiology, and Experimental Studies in Humans and Animals. Diabetes Care. 1995, Vol. 18, Supplement 2, pages A2-A8.	1-7
A	WILMORE et al. Genetics, Response to Exercise, and Risk Factors: The HERITAGE Family Study. World Review of Nutrition and Dietetics. 1997, Vol. 81, pages 72-83, especially pages 72-73.	1-7

<input type="checkbox"/>	Further documents are listed in the continuation of Box C.	<input type="checkbox"/>	See patent family annex.
*	Special categories of cited documents:		
"A"	document defining the general state of the art which is not considered to be of particular relevance	"T"	later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or the art underlying the invention
"E"	earlier application or patent published on or after the international filing date	"X"	document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
"L"	document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	"Y"	document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
"O"	document referring to an oral disclosure, use, exhibition or other means	"&"	document member of the same patent family
"P"	document published prior to the international filing date but later than the priority date claimed		

Date of the actual completion of the international search 22 February 2000 (22.02.2000)	Date of mailing of the international search report 14 MAR 2000
Name and mailing address of the ISA/US Commissioner of Patents and Trademarks Box PCT Washington, D.C. 20231 Facsimile No. (703)305-3230	Authorized officer Juliet C. Einsmann Telephone No. (703) 308-0196

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US99/26019

Continuation of B. FIELDS SEARCHED Item 3: MEDLINE, CAPLUS, WEST (US PATENTS), BIOSIS, EMBASE, SCISEARCH

search terms: diabetes, exercise, allele, polymorphis..., genotype